Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with
Filed: 2026-10-06 AccNo: 0001493152-26-045866 Size: 228 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Microbot Medical (NASDAQ: MBOT) announced expansion of its LIBERTY robotic system across the U.S., securing its first California customer and expanding into North Carolina. The company is on track to establish 12 sales territories by year-end, hired additional sales leadership, and expects positive gross margins in 2027 through manufacturing efficiencies. International expansion into Asia and Middle East is in advanced stages with CE mark approval expected in late Q4 2026 or early Q1 2027.